Bone Marrow Transplantation & Gene Therapy
The ESID Bone Marrow Transplantation and Gene Therapy Working Party works very closely with the EBMT Inborn Errors Working Party (IEWP). The aim of the working party is to improve the outcome of transplant and gene therapy for severe congenital immunodeficiencies through:
1) enhanced interaction between centres involved in the application of BMT to treat severe congenital immunodeficiencies
2) undertaking retrospective collaborative studies to look at the outcome of transplant for these conditions
3) education of individuals involved in the care of severe immunodeficiencies
4) development of guidelines for treatment of severe congenital immunodeficiencies
5) the development and use of a common registry to document and analyse results of treatment
These conditions have a number of challenging aspects in common: their recognition and correct identification may be difficult, requiring special clinical experience and laboratory expertise. Patients are usually infants at high risk of rapidly developing life-threatening complications, particularly from infections. Their management requires a well-coordinated and structured approach and the prognosis can be extremely poor unless haematopoietic stem cell transplantation or more recently gene therapy can be applied in a timely and appropriate manner.
The rarity of the conditions is such that collection of meaningful data is only possible through collaboration between centres and the strength of the WP has been the excellent collaborative approach taken by European transplant groups. This has resulted in a number of major publications which have been extremely important in guiding management both in Europe and worldwide.
Members of the WP meet at least twice yearly, once at the main EBMT meeting in the spring and then a dedicated 2 day meeting in the Autumn. The autumn meeting provides an opportunity to discuss work in progress, decide on common protocol and guidelines for treatment, formulate prospective and retrospective studies, and exchange experience.
More information
A study on the outcome of transplant for antibody deficiency and CVID in collaboration with EBMT Inborn Errors WP and ESID BMT and Clinical WP.
More information
Annual Inborn errors meeting report by Bobby Gaspar
More information
More information
A. Introduction
Primary immunodeficiencies are rare heterogeneous disorders. Patients present with a variety of clinical symptoms and a wide range of infections and other complications. Treatment by bone marrow transplantation is increasingly successful (reference: Antoine C, et al. The Lancet 2003;361:553-60; Gennery et al., JACI 2010;126:602-610) and the joint EBMT/ESID Working Party has played a pivotal role designing and developing the guidelines which have led to this success.
More information
Bobby Gaspar is running a project to collect data on the presentation, management and outcome of XLP patients who have a confirmed mutation in the SAP gene (SH2D1A). Data is collected both on paper forms as well as in the ESID Online Database Subregistry for XLP (SH2D1A).
More information
More information
On behalf of our working group we kindly invite you to join our survey.
Online submission via the ESID Database is now open!
More information